RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Castle Biosciences Stock

Castle Biosciences Stocks 2024

Castle Biosciences Stocks

26.8 M

Ticker

CSTL

ISIN

US14843C1053

WKN

A2PNH3

In 2024, Castle Biosciences had 26.8 M outstanding stocks, a 0% change from the 26.8 M stocks in the previous year.

The Castle Biosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e26.8
2028e26.8
2027e26.8
2026e26.8
2025e26.8
2024e26.8
202326.8
202226.1
202125.1
202018.9
201917.1
201816
201716

Castle Biosciences shares outstanding

The number of shares was Castle Biosciences in 2023 — This indicates how many shares 26.802 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Castle Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Castle Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Castle Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Castle Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Castle Biosciences Aktienanalyse

What does Castle Biosciences do?

Castle Biosciences Inc is an American company that was founded in 2007. The company's goal is to develop and distribute innovative diagnostic tests for various types of cancer. Castle Biosciences is headquartered in Friendswood, Texas, and has numerous branches throughout North America. The company currently has around 200 employees and a strong management team. The business model of Castle Biosciences is based on the development and marketing of personalized medical tests that can help improve the diagnosis and treatment of cancer patients. Castle Biosciences primarily offers its tests through doctors and medical facilities. The company specializes in the development of prognostic and predictive tests that can provide doctors with important information to create personalized treatment plans for their patients. Castle Biosciences has several divisions specializing in different types of cancer. One of the most important divisions is in the field of dermatology, developing and distributing tests for the diagnosis and prognosis of melanoma and other skin cancer types. Castle Biosciences also offers personalized tests for cancer of the eyes, stomach, and lung. Another important product of Castle Biosciences is the DecisionDx-Melanoma test. The test is a molecular diagnostic procedure that predicts the likelihood of melanoma recurrence. The test utilizes proprietary gene expression analysis to assess the risk of melanoma recurrence within five years after tumor removal. The results of the test can help minimize the risk of relapse and improve the patients' quality of life. Castle Biosciences has also developed the DecisionDx-UM test, a diagnostic test for uveal melanoma, a rare cancer affecting the eyes. The DecisionDx-UM test uses RNA expression to predict the individual metastatic risk of the cancer and support optimal medical management. The company has also specialized in the development of tests for gastric cancer. The CastleTest™ analyzes the transcription activity of 11 genes to determine the risk of tumor spread from the primary gastric location. Castle Biosciences has made significant progress in recent years and continues to expand through the introduction of new products and services in the market. The company emphasizes a certification program and continuous training of doctors and pathologists to support test performance. Additionally, Castle Biosciences has brought together additional knowledge and expertise through partnerships with other companies and institutions to develop innovative solutions for a wider range of cancer types. Overall, Castle Biosciences is a company specializing in innovative solutions for the diagnosis and prognosis of cancer. The personalized tests from Castle Biosciences have the potential to improve the quality of life for cancer patients by providing additional information for individual treatment plans. With its dedicated workforce and successful products, Castle Biosciences will continue to play an important role in the fight against cancer. Castle Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Castle Biosciences's Shares Outstanding

Castle Biosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Castle Biosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Castle Biosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Castle Biosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Castle Biosciences stock

How many stocks are there of Castle Biosciences?

The current number of stocks of Castle Biosciences is 26.8 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Castle Biosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Castle Biosciences evolved in recent years?

The number of shares of Castle Biosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Castle Biosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Castle Biosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Castle Biosciences pay?

Over the past 12 months, Castle Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Castle Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Castle Biosciences?

The current dividend yield of Castle Biosciences is .

When does Castle Biosciences pay dividends?

Castle Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Castle Biosciences?

Castle Biosciences paid dividends every year for the past 0 years.

What is the dividend of Castle Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Castle Biosciences located?

Castle Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Castle Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Castle Biosciences from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Castle Biosciences pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Castle Biosciences in the year 2023?

In the year 2023, Castle Biosciences distributed 0 USD as dividends.

In which currency does Castle Biosciences pay out the dividend?

The dividends of Castle Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Castle Biosciences

Our stock analysis for Castle Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Castle Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.